SIGNIFOR 0.3MG/ML 30 AMP

Indication For the treatment of Cushing�s disease specifically for those patients whom pituitary surgery has not been curative or is not an option. Mechanism of action Pasireotide activates a broad spectrum of somatostatin receptors exhbiting a much higher binding affinity for somatostatin receptors 1 3 and 5 than octreotide in vitro as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushings disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH) glucagon and insulin.